Conning Inc. Decreases Position in AbbVie Inc. $ABBV

Conning Inc. lowered its position in AbbVie Inc. (NYSE:ABBV) by 13.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 166,081 shares of the company’s stock after selling 24,942 shares during the period. AbbVie accounts for 1.3% of Conning Inc.’s portfolio, making the stock its 6th largest holding. Conning Inc.’s holdings in AbbVie were worth $38,454,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Marshall & Sullivan Inc. WA acquired a new position in AbbVie in the second quarter worth $25,000. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the second quarter valued at about $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie in the second quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in AbbVie during the 2nd quarter worth about $36,000. Finally, Delos Wealth Advisors LLC bought a new stake in AbbVie during the 2nd quarter worth about $39,000. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ABBV shares. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research note on Tuesday, November 4th. Citigroup dropped their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. JPMorgan Chase & Co. increased their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Raymond James Financial set a $256.00 target price on AbbVie in a research report on Monday, November 3rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Stock Performance

Shares of AbbVie stock opened at $222.21 on Thursday. The stock has a market capitalization of $392.72 billion, a price-to-earnings ratio of 168.34, a PEG ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a fifty day moving average of $226.94 and a two-hundred day moving average of $216.08.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the business posted $3.00 EPS. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 496.97%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie says it will build out its presence in the fast-growing obesity-treatment market, leveraging a weight‑loss drug it licensed from Danish biotech Gubra — opens a new growth avenue beyond core franchises. AbbVie plans to build out its presence in obesity market
• Positive Sentiment: AbbVie reached a three‑year drug‑pricing pact with the U.S. administration that includes a $100 billion U.S. R&D/investment pledge and exemptions from certain tariffs — reduces policy/tariff risk and signals regulatory cooperation. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to a ~$5.6B licensing partnership with RemeGen to access a PD‑1xVEGF bispecific oncology candidate — expands oncology pipeline and potential future revenue streams. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: AbbVie is acquiring a drug‑delivery system and an Arizona manufacturing facility from West Pharma and is spending on U.S. manufacturing capacity (including a reported $175M plant) — strengthens supply chain and supports on‑shore production. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Management’s full transcript from the J.P. Morgan Healthcare Conference provides detail on strategy and pipeline positioning — useful for modeling but no single market‑moving surprise in the transcript itself. AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Several analyst/market pieces highlight bullish sentiment and long‑term value arguments for ABBV; these can support momentum but reflect secondary commentary rather than new company facts. Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
• Neutral Sentiment: AbbVie joined industry calls for the FDA to update post‑approval change rules — a regulatory engagement that could benefit manufacturers broadly if successful but is a longer‑term policy push. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Negative Sentiment: The U.S. drug‑pricing agreement includes commitments to lower some U.S. prices and Medicaid impacts — this could weigh on near‑term revenue/margins for affected products even as tariff/other risks are reduced. ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.